ACOG CEO: “In the face of misinformation and vaccine hesitancy, a strong, evidence-based recommendation...from a trusted clinician can go a long way."
The American College of Obstetricians and Gynecologists (ACOG) has released updated clinical guidance recommending vaccination against COVID-19, influenza, and respiratory syncytial virus (RSV) during pregnancy. The three practice advisories present the current evidence base and emphasize both maternal and infant protection.
“It is well documented that respiratory conditions can cause poor outcomes during pregnancy, with pregnant women facing both severe illness and threats to the health of their pregnancy. Thanks to vaccines, severe outcomes from respiratory infections are largely preventable,” Steven J. Fleischman, MD, MBA, president of ACOG, said in a statement. “ACOG’s updated respiratory guidance documents repeat what we have long known: that vaccines continue to be the best tool available for pregnant patients to protect themselves and their infants from these viruses.”
The updated COVID-19 advisory recommends that patients receive an updated COVID-19 vaccine or booster at any point during pregnancy, when planning pregnancy, postpartum, or while lactating. Data show that vaccination reduces maternal morbidity, preterm birth, stillbirth, and severe maternal morbidity.
Infants of vaccinated mothers had greater antibody persistence compared with those whose mothers had infection without vaccination. During the 2023–24 respiratory virus season, fewer than 5% of mothers whose infants were hospitalized for COVID-19 had received the vaccine during pregnancy. "Infants continue to be hospitalized for COVID-19 at higher rates than all age groups except adults 75 years and older," according to the ACOG statement.
In its influenza advisory, ACOG continues to recommend inactivated or recombinant influenza vaccination during any trimester of pregnancy, ideally before the start of influenza season but at any time while influenza is circulating. The advisory specifies that the newly approved live-attenuated intranasal influenza vaccine (FluMist; AztraZeneca) is not indicated in pregnancy. However, it is safe to use postpartum, including among women who are lactating and prefer intranasal administration. The advisory also includes guidance on antiviral treatment for influenza during pregnancy.
"Decades of data have informed ACOG’s long-standing recommendation in support of vaccination against the seasonal flu during pregnancy. Unfortunately, data show that in recent years, less than half of pregnant patients have chosen to receive the flu vaccine,” Neil S. Silverman, MD, said in the ACOG statement.
Recommendations for administration of the bivalent RSV PreF vaccine call for vaccination between 32 0/7 and 36 6/7 weeks of gestation for women:
Infants of mothers who decline maternal RSV vaccination should receive monoclonal antibody protection at birth, the advisory recommends.
“The RSV vaccine provides our pregnant patients with the ability to protect their infants against severe respiratory illness before they are even born,” Brenna Hughes, MD, said.
All 3 maternal respiratory vaccines may be administered simultaneously, the statement advises. “In the face of misinformation and vaccine hesitancy, a strong, evidence-based recommendation in support of vaccination from a trusted clinician can go a long way toward encouraging our patients to protect themselves and their pregnancies,” Sandra E. Brooks, MD, MBA, chief executive officer of ACOG, stated. “As respiratory illness season begins, it is crucial that my fellow health care professionals actively support and recommend COVID-19, flu, and RSV vaccines for pregnant patients.”
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.